Evidence-driven updates across biotech and AI

Articles, whitepapers and podcasts from our team and advisors.

Whitepapers

Rebuilding a Brittle Market: Regulatory Reform and the Return of Innovation in Osteoporosis

Osteoporosis, a condition where bones become weak and brittle due to loss of bone density, is often seen as a natural part of aging, but it is more accurately a chronic disease caused by disrupted bone remodeling. 10 million Americans over age 50 have osteoporosis, and another 43 million have low bone mass.[1] Despite this, many patients remain undiagnosed and untreated. While existing therapies can reduce fracture risk, they do not provide a safe, effective long-term solution for a disease that develops over decades. Progress in the field has been slowed not only by biology but also by demanding regulatory requirements that de-incentivized innovation. Historically, the FDA required large, lengthy, and expensive phase 3 trials. These trials often involved more than 7,000 patients over 3–5 years to show reductions in fracture risk, even when improvements in bone mineral density (BMD) were observed. In December 2025, the FDA updated its approach, accepting total hip BMD, measured by dual-energy X-ray absorptiometry (DXA), as a validated surrogate endpoint for postmenopausal osteoporosis trials. [2],[3] While this does not solve the underlying biology, it significantly reduces the time, cost, and complexity of clinical development, enabling clinical proof-of-concept in a 24-month trial and making osteoporosis a more attractive area for innovation and investment.

See More
Whitepapers

God Bless the Private Sector: How Private Funding is Bridging the Gap

Publicly funded basic research has long served as the foundation for breakthroughs. Yet proposed federal cuts, including reductions to the NSF and NIH, now threaten the early-stage research that the private sector traditionally does not fund. These changes have already stalled projects, eliminated jobs, and raised concerns about broader delays in scientific progress. At the same time, the United States faces intensifying competition with China, whose sustained investment in early-stage biotech has accelerated its global share of drug development. Although the US retains leadership in total R&D value, the trend signals growing vulnerability, one seemingly at odds with the administration’s broader “America First” agenda. The launch of the Genesis Mission, with its emphasis on AI-enabled science and biotechnology as a domain of national importance, hints at a potential restructuring rather than an abandonment of federal scientific priorities. In this environment, the private sector has emerged as an essential stabilizing force. As public funding recedes, venture capital and philanthropy must intervene earlier in the research lifecycle. This shift can bring rigorous private-sector diligence to basic science, likely focusing resources on fewer projects but with greater efficiency. To handle this complexity, biology-specific AI tools will shift from optional luxuries to indispensable necessities. Ultimately, this disruption offers a chance to modernize our infrastructure: building a resilient ecosystem capable of expanding, not just restoring, American scientific progress.

See More
AllPodcastsWhitepapersArticles
Whitepapers

Rebuilding a Brittle Market: Regulatory Reform and the Return of Innovation in Osteoporosis

Osteoporosis, a condition where bones become weak and brittle due to loss of bone density, is often seen as a natural part of aging, but it is more accurately a chronic disease caused by disrupted bone remodeling. 10 million Americans over age 50 have osteoporosis, and another 43 million have low bone mass.[1] Despite this, many patients remain undiagnosed and untreated. While existing therapies can reduce fracture risk, they do not provide a safe, effective long-term solution for a disease that develops over decades. Progress in the field has been slowed not only by biology but also by demanding regulatory requirements that de-incentivized innovation. Historically, the FDA required large, lengthy, and expensive phase 3 trials. These trials often involved more than 7,000 patients over 3–5 years to show reductions in fracture risk, even when improvements in bone mineral density (BMD) were observed. In December 2025, the FDA updated its approach, accepting total hip BMD, measured by dual-energy X-ray absorptiometry (DXA), as a validated surrogate endpoint for postmenopausal osteoporosis trials. [2],[3] While this does not solve the underlying biology, it significantly reduces the time, cost, and complexity of clinical development, enabling clinical proof-of-concept in a 24-month trial and making osteoporosis a more attractive area for innovation and investment.

See More
Whitepapers

Drug Development: The Alchemy of Hope

The journey from an idea to a commercialized medicine is, at its core, a human story.

See More
Whitepapers

From Blunt Sedation to Precise Disease Control: Insights into Anti-Seizure Medications

Living with epilepsy can feel like walking in a minefield: patients often feel like they need to tiptoe through their lives, fearful that any misstep or obscure catalyst can trigger a (potentially deadly) seizure. In the non-epileptic brain, neuron ensembles operate with one another in precise and synchronized coordination, giving rise to normal cognition, perception, and movement. In many epilepsy cases, patients develop seizures after an injury or other insult (e.g., traumatic brain injury, stroke, tumors, etc.) induces a structural malformation in the brain, serving as the source of abnormal discharges between neurons that manifest as seizures. In other cases, mutations in a variety of genes can disrupt the normal balance between excitation and inhibition within neurons, representing direct genetic causes of epilepsy.

See More
Whitepapers

God Bless the Private Sector: How Private Funding is Bridging the Gap

Publicly funded basic research has long served as the foundation for breakthroughs. Yet proposed federal cuts, including reductions to the NSF and NIH, now threaten the early-stage research that the private sector traditionally does not fund. These changes have already stalled projects, eliminated jobs, and raised concerns about broader delays in scientific progress. At the same time, the United States faces intensifying competition with China, whose sustained investment in early-stage biotech has accelerated its global share of drug development. Although the US retains leadership in total R&D value, the trend signals growing vulnerability, one seemingly at odds with the administration’s broader “America First” agenda. The launch of the Genesis Mission, with its emphasis on AI-enabled science and biotechnology as a domain of national importance, hints at a potential restructuring rather than an abandonment of federal scientific priorities. In this environment, the private sector has emerged as an essential stabilizing force. As public funding recedes, venture capital and philanthropy must intervene earlier in the research lifecycle. This shift can bring rigorous private-sector diligence to basic science, likely focusing resources on fewer projects but with greater efficiency. To handle this complexity, biology-specific AI tools will shift from optional luxuries to indispensable necessities. Ultimately, this disruption offers a chance to modernize our infrastructure: building a resilient ecosystem capable of expanding, not just restoring, American scientific progress.

See More
Whitepapers

The Next Era of Care for Neurodegenerative Disease

Neurodegeneration is a gradual loss of brain function that unfolds over decades before symptoms appear. It isn’t quite a silent killer like heart disease or cancer; it’s an emotional long goodbye. While neurodegeneration manifests in many ways, severe memory loss from dementia is among the most common outcome of this irreparable brain damage. Each year, millions of individuals with dementia experience progressive losses in memory, personality, and functional independence. Countless family members and caregivers bear witness to this devastating life deterioration. Despite its toll on society, innovations combatting neurodegenerative disease have lagged far behind advances in heart disease that produced statins and the rapidly expanding arsenal of cancer-fighting drugs. These shortcomings are not due to lack of funding or interest from society, but instead because drug development for the brain faces complex challenges that other therapeutic areas do not. Alzheimer’s Disease (AD) is the most common form of neurodegeneration and is responsible for ~70% of dementia cases. Over the past two years, the AD drug development space has started to turn a corner, highlighted by the first two disease modifying drug approvals. For the first time, patients have drugs that modestly slow cognitive decline, giving hope to both the patient and drug development communities.At Luma Group, we believe that these innovations are just the tip of the iceberg. The clinical learnings from AD on optimal diagnosis, delivery, and patient selection will catalyze further innovation in neurodegenerative proteinopathies like Parkinson’s disease, Lewy body dementia, Huntington’s disease, and amyotrophic lateral sclerosis (ALS). This whitepaper uses AD as a case study to explore the future of care in neurodegenerative disease. We present the current understanding of AD disease biology and treatment landscape for a generalist audience and give our vision of the next era of care in AD: a world where AD diagnosis is as easy as blood test and physicians can choose from a broad armamentarium of therapies to tackle the multifaceted features of neurodegeneration.

See More
Whitepapers

The Case for Venture Capital in Biotechnology

There are many perceptions of what a venture capitalist (VC) is. In the biotech space, VCs are enigmatic because many of us never imagined becoming VCs, and many future VCs might have no idea they’re headed down that path either. My story, like many in biotech, started with a passion to help sick people. I was fortunate to discover my passion at the age of six, when I told my parents that I wanted to be a genetic engineer. I didn’t fully understand what that entailed, but the film Jurassic Park sparked my curiosity. I was fascinated by the idea that nature had invented biological Legos called DNA that could be assembled to create humans, sea slugs, bananas, bacteria, mold, and, most intriguingly, entirely new life forms. Less than two decades later, I received my PhD in Molecular and Cellular Biology. I loved deciphering nature’s clues and genetic codes to figure out the “how” and “why” in nature’s playbook. However, I didn’t yet know how to translate this knowledge from the lab into life-saving therapies. I continued my research journey post-PhD and eventually landed an industry postdoc position at Pfizer. At Pfizer, I soaked up every fact, lesson, piece of jargon, and process required to take an initial discovery and turn it into a drug. At this moment, something clicked for me: my true passion wasn’t just making discoveries; it was figuring out how to transform those discoveries into medicines capable of helping patients. My time at Pfizer also made it clear that I wasn’t ready to join an organization as large as Pfizer long-term. Thankfully, after years of trying different career trajectories and with the help of some great mentors, it became clear that biotech venture capital uniquely aligned both my personal goals: contributing to life-changing therapies, and professional goals: being able to earn a living while pursuing my personal passion. As they say, “Do what you love, and you’ll never work a day in your life.”

See More